ImmunityBio’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways
On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…
-
-
Moderna announced first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in adolescents
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
-
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
-
First peer-reviewed results of phase 3 human trials of University of Oxford vaccine demonstrated efficacy
On Dev. 8, 2020, University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials…
-
Switzerland exercised increased option for 7.5 million doses of mRNA vaccine against COVID-19 (mRNA-1273)
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
-
Serum Institute applied for emergency use authorisation for COVID-19 vaccine
On Dec. 7, 2020, the Serum Institute of India (SII) announced that it had applied to Drugs Controller…
-
INOVIO dosed first subject in phase 2 segment of INNOVATE phase 2/3 trial for INO-4800 to prevent COVID-19
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
-
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
-
Canada exercised increased option for total of 40 million doses of mRNA vaccine candidate against COVID-19
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
-
Chimerix announced FDA acceptance of NDA for brincidofovir as a medical countermeasure for smallpox
On Dec. 7, 2020, Chimerix announced the U.S. Food and Drug Administration (FDA) had accepted the filing of a…
-
High-dose influenza vaccine showed no additional benefit for heart disease patients
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…
-
VBI Vaccines partnered with Syneos Health for commercialization of prophylactic 3-antigen hepatitis B vaccine
On Dec. 4, 2020, VBI Vaccines and Syneos Health announced a partnership for the commercialization of VBIﾒs 3-antigen…
-
INOVIO expanded global manufacturing consortium for COVID-19 vaccine candidate with Kaneka Eurogentec
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
-
CDC’s ACIP issued Interim recommendation for allocating initial supplies of COVID-19 vaccine
On Dec. 3, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended, as interim guidance, that both 1)…
-
Moderna updated on clinical development and production of Its COVID-19 vaccine candidate
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
-
UK medicines regulator approved first UK COVID-19 vaccine
On Dec. 2, 2020, the first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, was given approval for…
-
Codex DNA released new synthetic genomes for the fight against COVID-19
On Dec. 2, 2020, Codex DNA announced the release of seven new synthetic SARS-CoV-2 genomes for use in…
-
Pfizer and BioNTech achieved first authorization in the world for a vaccine to combat COVID-19
On Dec. 2, 2020, Pfizer and BioNTech announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in…
-
Pfizer and BioNTech submitted application for Conditional Marketing Authorization for COVID-19 vaccine
On Dec. 1, 2020, Pfizer and BioNTech announced they had submitted on Monday, November 30, 2020, a formal…
-
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, a City of Hope investigational vaccine produced strong protective immunity against SARS-CoV-2, including neutralizing antibodies…
-
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
-
Novavax announced COVID-19 vaccine clinical development progress
On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored…
-
Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
-
Moderna announced EC approval of purchase agreement for 80 million doses of mRNA COVID-19 vaccine
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
-
BioNTech and Fosun Pharma announced start of phase 2 clinical trial of mRNA COVID-19 vaccine in China
On Nov. 25, 2020, BioNTech and Shanghai Fosun Pharmaceutica jointly announced that their lead mRNA COVID-19 vaccine candidate…
-
Roche announced FDA approval of Xofluza for prevention of influenza following contact with infected person
On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…
-
NeuroRx and Relief announced successful results from expanded use of RLF-100 in patients with COVID-19
On Feb. 24, 2021, NeuroRx, announced that the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the…
-
MediciNova announced initiation of master virus seed stock production for intranasal COVID-19 vaccine
On Nov. 24, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
-
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
On Nov. 23, 2020, AstraZeneca announced positive high-level results from an interim analysis of clinical trials of AZD1222…
-
Oxford University reported breakthrough on global COVID-19 vaccine
On Nov. 23, 2020, the University of Oxford, in collaboration with AstraZeneca, announced interim trial data from its…
